Targeting regulatory T cells in anti‐PD‐1/PD‐L1 cancer immunotherapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting regulatory T cells in anti‐PD‐1/PD‐L1 cancer immunotherapy
Authors
Keywords
-
Journal
SCANDINAVIAN JOURNAL OF IMMUNOLOGY
Volume 95, Issue 3, Pages -
Publisher
Wiley
Online
2021-12-22
DOI
10.1111/sji.13129
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy
- (2021) Rajasekharan Somasundaram et al. Nature Communications
- Targeting adenosine and regulatory T cells in cancer immunotherapy
- (2021) Alexey Churov et al. HUMAN IMMUNOLOGY
- Common clonal origin of conventional T cells and induced regulatory T cells in breast cancer patients
- (2021) Maria Xydia et al. Nature Communications
- Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
- (2021) Davide Melisi et al. Journal for ImmunoTherapy of Cancer
- Wnt/β-Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma
- (2021) Alexander Chehrazi-Raffle et al. Cancers
- The Ratio of GrzB+ − FoxP3+ over CD3+ T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma
- (2021) Giosuè Scognamiglio et al. Cancers
- TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma
- (2021) Zhouhong Ge et al. Cellular and Molecular Gastroenterology and Hepatology
- The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy
- (2021) Sashi Kandel et al. CANCER LETTERS
- Control of regulatory T‐cell differentiation and function by T‐cell receptor signalling and Foxp3 transcription factor complexes
- (2020) Masahiro Ono IMMUNOLOGY
- Phase II study of nivolumab and relatlimab in advanced mismatch repair deficient (dMMR) cancers resistant to prior PD-(L)1 inhibition.
- (2020) Katherine M. Bever et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis
- (2020) Leitao Sun et al. Scientific Reports
- Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer
- (2020) Selene Ottonello et al. Frontiers in Immunology
- Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).
- (2020) Delvys Rodriguez-Abreu et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I combination study of vigil and atezolizumab in recurrent/refractory advanced-stage ovarian cancer: Efficacy assessment in BRCA1/2-wt patients.
- (2020) Rodney Paul Rocconi et al. JOURNAL OF CLINICAL ONCOLOGY
- First‐in‐human phase 1 study of MK‐1248, an anti–glucocorticoid‐induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors
- (2020) Ravit Geva et al. CANCER
- The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
- (2020) Shogo Kumagai et al. NATURE IMMUNOLOGY
- Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer
- (2020) Grégoire de Streel et al. Nature Communications
- Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
- (2020) Jin-Yu Sun et al. Biomarker Research
- Dual roles of myeloid‑derived suppressor cells induced by Toll‑like receptor signaling in cancer (Review)
- (2020) Hongyue Zhou et al. Oncology Letters
- Immunometabolism of regulatory T cells in cancer
- (2020) Mario Galgani et al. MOLECULAR ASPECTS OF MEDICINE
- The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial
- (2019) Charlotte M. Huijts et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas
- (2019) E. Dodagatta-Marri et al. Journal for ImmunoTherapy of Cancer
- Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
- (2019) Yosuke Togashi et al. Nature Reviews Clinical Oncology
- Overall responses with coordinated pembrolizumab and high dose IL-2 (5-in-a-row schedule) for therapy of metastatic clear cell renal cancer: A single center, single arm trial.
- (2019) Jonathan Alexander Chatzkel et al. JOURNAL OF CLINICAL ONCOLOGY
- AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies.
- (2019) John D. Powderly et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
- (2019) Takahiro Kamada et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Tumor Microenvironment Innately Modulates Cancer Progression
- (2019) Dominique C. Hinshaw et al. CANCER RESEARCH
- PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance
- (2019) Vivek Verma et al. NATURE IMMUNOLOGY
- Concise Review: Metabolism and Gut Microbiota in Cancer Immunoediting, CD8/Treg Ratios, Immune Cell Homeostasis, and Cancer (Immuno)Therapy
- (2019) Irina Kareva STEM CELLS
- Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade
- (2019) Nicolas Jacquelot et al. CELL RESEARCH
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD8+ T-cell exhaustion in cancer: mechanisms and new area for cancer immunotherapy
- (2018) Qi-Feng He et al. Briefings in Functional Genomics
- T-cell cross-reactivity may explain the large variation in how cancer patients respond to checkpoint inhibitors
- (2018) Mouldy Sioud SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
- (2018) Rikke B. Holmgaard et al. Journal for ImmunoTherapy of Cancer
- Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
- (2018) Judith A. Seidel et al. Frontiers in Oncology
- Abstract CT180: Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors
- (2018) Lillian L. Siu et al. CANCER RESEARCH
- PD-1 Inhibitory Receptor Downregulates Asparaginyl Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory T Cells
- (2018) Chaido Stathopoulou et al. IMMUNITY
- Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma
- (2018) Sarah Harris-Bookman et al. INTERNATIONAL JOURNAL OF CANCER
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- The Immunoscore is a Superior Prognostic Tool in Stages II and III Colorectal Cancer and is Significantly Correlated with Programmed Death-Ligand 1 (PD-L1) Expression on Tumor-Infiltrating Mononuclear Cells
- (2018) Takato Yomoda et al. ANNALS OF SURGICAL ONCOLOGY
- Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
- (2018) Moshe Sade-Feldman et al. CELL
- Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers-Letter
- (2018) Roberto Ferrara et al. CLINICAL CANCER RESEARCH
- Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
- (2017) Suzanne George et al. IMMUNITY
- Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
- (2017) Frederick Arce Vargas et al. IMMUNITY
- Identification of essential genes for cancer immunotherapy
- (2017) Shashank J. Patel et al. NATURE
- In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
- (2017) Robert T. Manguso et al. NATURE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
- (2017) Guillermo De Velasco et al. Cancer Immunology Research
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- Natural Killer T Cells in Cancer Immunotherapy
- (2017) Shiny Nair et al. Frontiers in Immunology
- Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma
- (2017) Nicolas Jacquelot et al. OncoImmunology
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model
- (2016) Baihao Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- Colorectal cancer cell-derived extracellular vesicles induce phenotypic alteration of T cells into tumor-growth supporting cells with transforming growth factor-β1-mediated suppression
- (2016) Nami Yamada et al. Oncotarget
- Regulatory T cells with multiple suppressive and potentially pro-tumor activities accumulate in human colorectal cancer
- (2016) Eleonora Timperi et al. OncoImmunology
- Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients
- (2015) K. Kurose et al. CLINICAL CANCER RESEARCH
- RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
- (2015) S. Loi et al. CLINICAL CANCER RESEARCH
- TIGIT predominantly regulates the immune response via regulatory T cells
- (2015) Sema Kurtulus et al. JOURNAL OF CLINICAL INVESTIGATION
- Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity
- (2015) Alison M. Paterson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-1 Upregulated on Regulatory T Cells during Chronic Virus Infection Enhances the Suppression of CD8+T Cell Immune Response via the Interaction with PD-L1 Expressed on CD8+T Cells
- (2015) Hyo Jin Park et al. JOURNAL OF IMMUNOLOGY
- Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions
- (2015) Danielle M. Lussier et al. JOURNAL OF IMMUNOTHERAPY
- Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
- (2015) Emanuela Romano et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
- (2015) Kim C. Ohaegbulam et al. TRENDS IN MOLECULAR MEDICINE
- TGF-β3-expressing CD4+CD25−LAG3+ regulatory T cells control humoral immune responses
- (2015) Tomohisa Okamura et al. Nature Communications
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- PD-1 regulates extrathymic regulatory T-cell differentiation
- (2014) Xiufen Chen et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Human OX40 tunes the function of regulatory T cells in tumor and nontumor areas of hepatitis C virus-infected liver tissue
- (2014) Silvia Piconese et al. HEPATOLOGY
- Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs
- (2014) Lei Lu et al. Journal of Translational Medicine
- Lymphocyte Activation Gene 3 (LAG-3) Modulates the Ability of CD4 T-cells to Be Suppressed In Vivo
- (2014) Nicholas M. Durham et al. PLoS One
- Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
- (2013) B. Allard et al. CLINICAL CANCER RESEARCH
- Staphylococcus aureusconvert neonatal conventional CD4+T cells into FOXP3+ CD25+ CD127lowT cells via the PD-1/PD-L1 axis
- (2013) Hardis Rabe et al. IMMUNOLOGY
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours
- (2013) Jérôme Galon et al. JOURNAL OF PATHOLOGY
- Intratumor Hypoxia Promotes Immune Tolerance by Inducing Regulatory T Cells via TGF-β1 in Gastric Cancer
- (2013) Bin Deng et al. PLoS One
- Induced and natural regulatory T cells in human cancer
- (2012) Theresa L. Whiteside et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- T Cell Receptor Stimulation-Induced Epigenetic Changes and Foxp3 Expression Are Independent and Complementary Events Required for Treg Cell Development
- (2012) Naganari Ohkura et al. IMMUNITY
- Activated but not resting regulatory T cells accumulated in tumor microenvironment and correlated with tumor progression in patients with colorectal cancer
- (2012) Yung-Chang Lin et al. INTERNATIONAL JOURNAL OF CANCER
- Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo
- (2012) J. Gotot et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Monoclonal antibody blockade of IL-2 receptor during lymphopenia selectively depletes regulatory T cells in mice and humans
- (2011) D. A. Mitchell et al. BLOOD
- The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells
- (2011) S. Amarnath et al. Science Translational Medicine
- Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients
- (2010) J. F. M. Jacobs et al. CLINICAL CANCER RESEARCH
- Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor
- (2009) Makoto Miyara et al. IMMUNITY
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now